The United States Food and Drug Administration (FDA) approved the drug flibanserin (sold under the brand name Addyi) for the treatment of women with hypo-active sexual desire disorder (HSDD) in August 2015. Australia hasn’t followed suit, though flib
Creators Muaz Nawaz, Daanyaal Ali, and Chirag Shah, from London’s Isaac Newton Academy, wanted to “make detecting harmful STIs safer than ever before” without invasive testing.